Mantle Cell Lymphoma
From the Journals
Ibrutinib plus venetoclax is active in mantle cell lymphoma
The combination appears to outperform the single agents when treating relapsed/refractory mantle cell lymphoma.
From the Journals
Time to rethink MCL treatment, trial design
Dr. Leonid Yavorkovsky of Kaiser Permanente San Jose Medical Center questions the traditional approach to treatment of class mantle cell lymphoma...
Conference Coverage
Outpatient CAR T infusions feasible using liso-cel
SALT LAKE CITY – Though most patients are admitted later, hospital stays are shorter with outpatient CAR T infusion.
From the Journals
Ibrutinib linked to invasive fungal infections
The researchers called for greater awareness of the potential for fungal infection in ibrutinib-treated patients.
From the Journals
Acalabrutinib shows less off-target activity in mantle cell lymphoma
The findings add to a growing body of evidence showing that BTK inhibition disrupts the tumor microenvironment.
From the Journals
NF-kappaB pathway could help solve resistance problem in mantle cell lymphoma
The research could set the stage for therapeutic targets to help avoid drug resistance in mantle cell treatment.
From the Journals
Triple therapy ups response in refractory mantle cell lymphoma
The results show that triple therapy with ibrutinib, lenalidomide, and rituximab should be evaluated in a randomized controlled trial.
From the Journals
VcR-CVAD yields high responses, ‘excellent’ survival in MCL
The moderate-intensity induction and maintenance regimen induced good responses in both younger and older patients.
Conference Coverage
BTK inhibitor zanubrutinib active in non-Hodgkin lymphomas
ATLANTA – Response rates ranged from 31% to 88% depending on the lymphoma subtype.
Conference Coverage
VIDEO - New lymphoma drug approvals: Clinical use, future directions
ATLANTA - At the ASH annual meeting, FDA representatives and clinicians discussed new lymphoma drug approvals and their use in the real-world...
Conference Coverage
VIDEO: Ibrutinib PFS is nearly 3 years in MCL patients who had one prior therapy
ATLANTA – Dr. Simon Rule discusses the implications of the study and how ibrutinib stacks up against other therapies for MCL.